NCT05537987View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

July 31, 2024

Conditions
Advanced Solid Tumors
Interventions
DRUG

ICP-723

3+3 dose escalation

Trial Locations (3)

10016

NYU-Langone Medical Center, New York

66506

University of Kansas Medical / Cancer Centers, Kansas City

98405

Northwest Medical Specialties, Tacoma

Sponsors
All Listed Sponsors
lead

InnoCare Pharma Inc.

INDUSTRY

NCT05537987 - Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter